SEC Form 4 · accession 0001127602-16-046112

INSULET CORP · PODD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Daniel J Levangie

Officer — President, Drug Delivery

Period of report

Mar 9, 2016

Accepted (ET)

Mar 11, 2016 · 4:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001145197

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 9, 2016	M	15,545	$15.14	A	25,358	D
Common Stock^F2,F1	Mar 9, 2016	S	7,600	$31.04	D	17,758	D
Common Stock^F1	Mar 10, 2016	M	9,455	$15.14	A	27,213	D
Common Stock^F3,F1	Mar 10, 2016	S	4,699	$30.65	D	22,514	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$15.14	Mar 9, 2016	M	15,545	D	—	Nov 1, 2021	Common Stock	15,545	9,455	D
Stock Option (Right to Buy)^F4	$15.14	Mar 10, 2016	M	9,455	D	—	Nov 1, 2021	Common Stock	9,455	0	D

Explanation of responses

F1Includes 1,000 restricted stock units granted on June 3, 2013, which vest on April 30, 2016; 2,000 restricted stock units granted on June 2, 2014, which vest one-half of the total units on April 30, 2016 and one-half of the total units on April 30, 2017; and 6,813 performance share units granted on April 1, 2015, which vest one-third of the total performance share units on April 1, 2016, one-third of the total performance share units on April 1, 2017 and one-third of the performance share units on April 1, 2018, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
F2The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $31.00 to $31.46. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F3The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $30.12 to $31.00. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F4This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.